Terms: = Ovarian cancer AND FGFR4, CD334, 2264, ENSG00000160867, P22455, MGC20292, TKF, JTK2
21 results:
1. Fibroblast Growth Factor Receptors and Ligands in Context of Bevacizumab Response in ovarian Carcinoma: An Exploratory Analysis of AGO-OVAR11/ICON-7.
Heublein S; Pfisterer J; du Bois A; Anglesio M; Aminossadati B; Bhatti I; Sehouli J; Wimberger P; Schochter F; Hilpert F; Hillemanns P; Kalder M; Schroeder W; Mahner S; Burges A; Canzler U; Gropp-Meier M; Jackisch C; Harter P; Kommoss S; Marmé F
Lab Invest; 2024 Apr; 104(4):100321. PubMed ID: 38154497
[TBL] [Abstract] [Full Text] [Related]
2. External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancer.
Wang Y; Broeks A; Giardiello D; Hauptmann M; Jóźwiak K; Koop EA; Opdam M; Siesling S; Sonke GS; Stathonikos N; Ter Hoeve ND; van der Wall E; van Deurzen CHM; van Diest PJ; Voogd AC; Vreuls W; Linn SC; Dackus GMHE; Schmidt MK
Eur J Cancer; 2023 Dec; 195():113401. PubMed ID: 37925965
[TBL] [Abstract] [Full Text] [Related]
3. Whole-exome sequencing reveals candidate high-risk susceptibility genes for endometriosis.
Nousiainen S; Kuismin O; Reinikka S; Manninen R; Khamaiseh S; Kuivalainen M; Terho A; Koivurova S; Niinimäki M; Salokas K; Varjosalo M; Ahtikoski A; Bützow R; Lindgren O; Uimari O; Vahteristo P
Hum Genomics; 2023 Oct; 17(1):88. PubMed ID: 37789421
[TBL] [Abstract] [Full Text] [Related]
4. First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors.
Harding JJ; Jungels C; Machiels JP; Smith DC; Walker C; Ji T; Jiang P; Li X; Asatiani E; Van Cutsem E; Abou-Alfa GK
Target Oncol; 2023 Mar; 18(2):181-193. PubMed ID: 36787089
[TBL] [Abstract] [Full Text] [Related]
5. A rare case of highly differentiated follicular carcinoma in ovary with fgfr4 Gly388Arg polymorphism: a case report and literature review.
Bao YT; Wang C; Huang W; Yao LQ; Yuan L
J Ovarian Res; 2022 Jun; 15(1):71. PubMed ID: 35701820
[TBL] [Abstract] [Full Text] [Related]
6. Maelstrom promotes tumor metastasis through regulation of fgfr4 and epithelial-mesenchymal transition in epithelial ovarian cancer.
He WP; Yang GP; Yang ZX; Shen HW; You ZS; Yang GF
J Ovarian Res; 2022 May; 15(1):55. PubMed ID: 35513870
[TBL] [Abstract] [Full Text] [Related]
7. Dual inhibition of fgfr4 and BCL-xL inhibits multi-resistant ovarian cancer with BCL2L1 gain.
Guo T; Gu C; Li B; Xu C
Aging (Albany NY); 2021 Aug; 13(15):19750-19759. PubMed ID: 34351305
[TBL] [Abstract] [Full Text] [Related]
8. Adjuvant chemotherapy vs. observation in stage I clear cell ovarian carcinoma: A systematic review and meta-analysis.
Bogani G; Ditto A; Lopez S; Bertolina F; Murgia F; Pinelli C; Chiappa V; Raspagliesi F
Gynecol Oncol; 2020 Apr; 157(1):293-298. PubMed ID: 31980220
[TBL] [Abstract] [Full Text] [Related]
9. Fibroblast growth factor receptor 4 (fgfr4) as detected by immunohistochemistry is associated with postoperative residual disease in ovarian cancer.
Heublein S; Anglesio MS; Marmé F; Kommoss S
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2251-2259. PubMed ID: 31385026
[TBL] [Abstract] [Full Text] [Related]
10. Penetrance estimates for
Evans DG; Woodward E; Harkness EF; Howell A; Plaskocinska I; Maher ER; Tischkowitz MD; Lalloo F
J Med Genet; 2018 Jul; 55(7):442-448. PubMed ID: 29483236
[TBL] [Abstract] [Full Text] [Related]
11. cancer-associated fibroblasts secrete FGF-1 to promote ovarian proliferation, migration, and invasion through the activation of FGF-1/fgfr4 signaling.
Sun Y; Fan X; Zhang Q; Shi X; Xu G; Zou C
Tumour Biol; 2017 Jul; 39(7):1010428317712592. PubMed ID: 28718374
[TBL] [Abstract] [Full Text] [Related]
12. The FGFR Landscape in cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.
Helsten T; Elkin S; Arthur E; Tomson BN; Carter J; Kurzrock R
Clin Cancer Res; 2016 Jan; 22(1):259-67. PubMed ID: 26373574
[TBL] [Abstract] [Full Text] [Related]
13. Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer.
Hu L; Cong L
Oncol Rep; 2015 Nov; 34(5):2683-91. PubMed ID: 26323668
[TBL] [Abstract] [Full Text] [Related]
14. FGF receptor genes and breast cancer susceptibility: results from the Breast cancer Association Consortium.
Agarwal D; Pineda S; Michailidou K; Herranz J; Pita G; Moreno LT; Alonso MR; Dennis J; Wang Q; Bolla MK; Meyer KB; Menéndez-Rodríguez P; Hardisson D; Mendiola M; González-Neira A; Lindblom A; Margolin S; Swerdlow A; Ashworth A; Orr N; Jones M; Matsuo K; Ito H; Iwata H; Kondo N; ; ; Hartman M; Hui M; Lim WY; Iau PT; Sawyer E; Tomlinson I; Kerin M; Miller N; Kang D; Choi J-; Park SK; Noh D-; Hopper JL; Schmidt DF; Makalic E; Southey MC; Teo SH; Yip CH; Sivanandan K; Tay W-; Brauch H; Brüning T; Hamann U; ; Dunning AM; Shah M; Andrulis IL; Knight JA; Glendon G; Tchatchou S; Schmidt MK; Broeks A; Rosenberg EH; van't Veer LJ; Fasching PA; Renner SP; Ekici AB; Beckmann MW; Shen C-; Hsiung C-; Yu J-; Hou M-; Blot W; Cai Q; Wu AH; Tseng C-; Van Den Berg D; Stram DO; Cox A; Brock IW; Reed MW; Muir K; Lophatananon A; Stewart-Brown S; Siriwanarangsan P; Zheng W; Deming-Halverson S; Shrubsole MJ; Long J; Shu X-; Lu W; Gao Y-; Zhang B; Radice P; Peterlongo P; Manoukian S; Mariette F; Sangrajrang S; McKay J; Couch FJ; Toland AE; ; Yannoukakos D; Fletcher O; Johnson N; dos Santos Silva I; Peto J; Marme F; Burwinkel B; Guénel P; Truong T; Sanchez M; Mulot C; Bojesen SE; Nordestgaard BG; Flyer H; Brenner H; Dieffenbach AK; Arndt V; Stegmaier C; Mannermaa A; Kataja V; Kosma V-; Hartikainen JM; Lambrechts D; Yesilyurt BT; Floris G; Leunen K; Chang-Claude J; Rudolph A; Seibold P; Flesch-Janys D; Wang X; Olson JE; Vachon C; Purrington K; Giles GG; Severi G; Baglietto L; Haiman CA; Henderson BE; Schumacher F; Marchand LL; Simard J; Dumont M; Goldberg MS; Labréche F; Winqvist R; Pylkäs K; Jukkola-Vuorinen A; Grip M; Devilee P; Tollenaar RA; Seynaeve C; García-Closas M; Chanock SJ; Lissowska J; Figueroa JD; Czene K; Eriksson M; Humphreys K; Darabi H; Hooning MJ; Kriege M; Collée JM; Tilanus-Linthorst M; Li J; Jakubowska A; Lubinski J; Jaworska-Bieniek K; Durda K; Nevanlinna H; Muranen TA; Aittomäki K; Blomqvist C; Bogdanova N; Dörk T; Hall P; Chenevix-Trench G; Easton DF; Pharroah PD; Arias-Perez JI; Zamora P; Benítez J; Milne RL
Br J Cancer; 2014 Feb; 110(4):1088-100. PubMed ID: 24548884
[TBL] [Abstract] [Full Text] [Related]
15. Identification of fgfr4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer.
Zaid TM; Yeung TL; Thompson MS; Leung CS; Harding T; Co NN; Schmandt RS; Kwan SY; Rodriguez-Aguay C; Lopez-Berestein G; Sood AK; Wong KK; Birrer MJ; Mok SC
Clin Cancer Res; 2013 Feb; 19(4):809-20. PubMed ID: 23344261
[TBL] [Abstract] [Full Text] [Related]
16. ovarian metastasis and other ovarian neoplasms in women with cervical cancer stage IA-IIA.
Ngamcherttakul V; Ruengkhachorn I
Asian Pac J Cancer Prev; 2012; 13(9):4525-9. PubMed ID: 23167373
[TBL] [Abstract] [Full Text] [Related]
17. Fibroblast growth factor receptor 4 gene (fgfr4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer.
Marmé F; Hielscher T; Hug S; Bondong S; Zeillinger R; Castillo-Tong DC; Sehouli J; Braicu I; Vergote I; Isabella C; Mahner S; Ferschke I; Rom J; Sohn C; Schneeweiss A; Altevogt P
Int J Cancer; 2012 Aug; 131(4):E586-91. PubMed ID: 22034009
[TBL] [Abstract] [Full Text] [Related]
18. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Gelmon KA; Tischkowitz M; Mackay H; Swenerton K; Robidoux A; Tonkin K; Hirte H; Huntsman D; Clemons M; Gilks B; Yerushalmi R; Macpherson E; Carmichael J; Oza A
Lancet Oncol; 2011 Sep; 12(9):852-61. PubMed ID: 21862407
[TBL] [Abstract] [Full Text] [Related]
19. Expression of fibroblast growth factor (FGF)-8 isoforms and FGF receptors in human ovarian tumors.
Valve E; Martikainen P; Seppänen J; Oksjoki S; Hinkka S; Anttila L; Grenman S; Klemi P; Härkönen P
Int J Cancer; 2000 Dec; 88(5):718-25. PubMed ID: 11072239
[TBL] [Abstract] [Full Text] [Related]
20. High expression of growth factors and growth factor receptors in ovarian metastases from ileal carcinoids: an immunohistochemical study of 2 cases.
Facco C; La Rosa S; Dionigi A; Uccella S; Riva C; Capella C
Arch Pathol Lab Med; 1998 Sep; 122(9):828-32. PubMed ID: 9740144
[TBL] [Abstract] [Full Text] [Related]
[Next]
